Fig. 2: Progression-free survival by MRD status after 18 cycles KRd. | Blood Cancer Journal

Fig. 2: Progression-free survival by MRD status after 18 cycles KRd.

From: Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Fig. 2

A PFS by NGS status after 18 cycles of KRd; B PFS by MALDI-TOF-MS status after 18 cycles of KRd; C PFS by LC-MS status after 18 cycles; D PFS of all NGS− patients, stratified by LC-MS status. Numbers in parentheses indicate events. KRd carfilzomib, lenalidomide, dexamethasone, LC-MS liquid chromatography mass spectrometry, MALDI-TOF-MS matrix‐assisted laser desorption ionization time‐of‐flight, MRD measurable residual disease, NGS next-generation sequencing; PFS progression-free survival.

Back to article page